Medicines | Horizonscan geneesmiddelen

Lisdexamfetamine ^IND Melatonine

ARI-0001 Brexucabtagene autoleucel ^IND Crisantaspase Obecabtagene autoleucel Ponatinib ^IND

Masitinib Sodium phenylbutyrate / ursodoxicoltaurine Tofersen ^IND

Decitabine / cedazuridine Eprenetapopt Gilteritinib ^IND Iomab-B Ivosidenib Magrolimab Quizartinib

Acalabrutinib ^IND Axicabtagene ciloleucel ^IND Crizotinib ^IND Epcoritamab Glofitamab Ibrutinib ^IND Lisocabtagene maraleucel ^IND Loncastuximab tesirine Pirtobrutinib Polatuzumab vedotin ^IND Tafasitamab Zamtocabtagene autoleucel Zanubrutinib ^IND

Aprocitentan Dabigatran ^G Proteïne C ^IND

Masitinib Tezepelumab

Bezlotoxumab Ceftobiprole Citric acid / lactic acid / potassium bitartrate ^IND Clindamycin Dalbavancine ^IND Durlobactam / sulbactam Eravacycline Gepotidacin Oritavancin diphosphate ^IND Ridinilazole SER 109 Tebipenem

Durvalumab

Neo-adjuvant durvalumab met chemotherapie en adjuvant durvalumab voor behandeling in patiënten met spier invasieve blaaskanker. ^IND Unresectable locally advanced or metastatic urothelial cancer in combination with tremelimumab and chemotherapy ^IND

Enfortumab vedotin ^IND Erdafitinib Inbakicept Nivolumab ^IND

Budesonide Etrasimod Etrolizumab ^IND Filgotinib ^IND Glepaglutide Mirikizumab

Risankizumab

Skyrizi is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van Crohn die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling. ^IND Indicated for UC (collitis ulcerosa) with demonstrated intolerance or inadequate response to conventional therapy and tofacitinib (not a biologic) and one or more biologic therapies. ^IND

Teduglutide ^IND Upadacitinib ^G

Dabrafenib / trametinib

Abemaciclib ^IND Atezolizumab ^IND Balixafortide Capivasertib Elacestrant Neratinib ^IND Olaparib ^IND Paclitaxel Palbociclib ^IND Pembrolizumab ^IND

Sacituzumab govitecan

For adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease Extension of indication to include treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ^IND

Tesetaxel

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy ^IND Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. ^IND Extension of indication to include treatment of HER2-low/ultra-low hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting. ^IND

Trastuzumab duocarmazine

Acalabrutinib

Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Extension of the existing CLL indication to include combination treatment with venetoclax for previously untreated patients. ^IND

Zanubrutinib

Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL). ^IND Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy ^IND

Asciminib

Ensifentrine

Baricitinib ^IND

Casirivimab / imdevimab

Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg . Extension of indication to include treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg and receiving supplemental oxygen, who have a negative SARS-CoV-2 antibody test result. ^IND

Molnupiravir PF-07321332 / ritonavir

Remdesivir

Treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment ^IND Treatment of paediatric patients (weighing at least 40kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 ^IND

Tixagevimab / cilgavimab

Pre-expositie profylaxe van COVID-19 bij volwassenen en adolescenten van 12 jaar en ouder met een lichaamsgewicht van tenminste 40 kilo Evusheld is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40kg) with COVID‑19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID‑19. ^IND

Cadonilimab Cemiplimab ^IND Lifileucel

Eflornithine / sulindac Fruquintinib Trifluridine / tipiracil

Lumacaftor / ivacaftor ^IND

Blarcamesine Donanemab Hydromethylthionine mesylaat Lecanemab

Agomelatine ^IND Bupropion / dextromethorphan

Bexagliflozine Dasiglucagon Dulaglutide ^IND Empagliflozine ^IND Finerenon ^IND Insulin Icodec Insulin lispro ^IND Polyethylene glycol loxenatide Regulatoire T-cellen (TREGS) Teplizumab Tirzepatide

Fordadistrogene movaparvovec Givinostat Golodirsen Losmapimod Vamorolone Viltolarsen

Cannabidiol ^IND Fenfluramine ^IND Ganaxolone

Aflibercept

Diabetic macular edema ^BS Eylea is indicated in preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease. ^IND

Avacincaptad pegol Bevacizumab-vikg Bimatoprost Botaretigene sparoparvovec

Faricimab

Treatment of neovascular (wet) age-related macular degeneration (nAMD). Treatment of visual impairment due to diabetic macular oedema (DME).

Laruparetigene zosaparvovec Lenadogene nolparvovec Pegcetacoplan ^IND Perfluorohexyloctane Phentolamine Polihexanide

Ranibizumab

Treatment of neovascular age-related macular degeneration (AMD) Wet age-related macular degeneration (AMD) ^BS

Reproxalap Sepofarsen Varenicline

Oteseconazole Rezafungin

Raltegravir ^BS Semzuvolimab

Atezolizumab ^IND Leukocyte interleukin Tislelizumab ^IND

Atogepant Dihydroergotamine Eptinezumab Lasmiditan Meloxicam / rizatriptan

Rimegepant

Acute treatment of migraine with or without aura in adults Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month

Emicizumab ^IND Eptacog beta (activated) Etranacogene dezaparvovec Fidanacogene elaparvovec Nonacog beta pegol ^IND Peboctocogene camaparvovec Valoctocogene roxaparvovec Vonicog alfa ^IND

Brentuximab vedotin ^IND

Axicabtagene ciloleucel ^IND Epcoritamab ^IND Hypericin Ibrutinib ^IND Lacutamab Mosunetuzumab Tisagenlecleucel-T ^IND Zanubrutinib ^IND

Baloxavir marboxil ^IND Cefepime / Enmetazobactam Cefepime/taniborbactam Fluticasone propionate

Atezolizumab ^IND Belzutifan Ilixadencel Lenvatinib ^IND

Pembrolizumab

Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). ^IND Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. ^IND

Alirocumab ^IND Bempedoic acid Evinacumab

Atezolizumab ^IND

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND Imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). ^IND

Tremelimumab

Arachidyl amido cholanoic acid

Maralixibat

Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 2 months of age and older ^IND

Obeticholic acid Odevixibat ^IND Resmetirom Seladelpar

Adagrasib

Atezolizumab

Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK‑positive NSCLC ^IND Atezolizumab subcutaneous in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC). ^IND Neoadjuvant atezolizumab with chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC). ^IND

Aumolertinib (mesilate) Cabozantinib ^IND Capmatinib

Cemiplimab

Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. ^IND LIBTAYO in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. ^IND

Domvanalimab

Durvalumab

Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations. ^IND 1L advanced NSCLC ^IND Completely resected NSCLC ^IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. ^IND

Ensartinib Lenvatinib ^IND Nintedanib ^G Nivolumab ^IND OSE-2101

Osimertinib

Osimertinib with platinum plus pemetrexed chemotherapy as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. ^IND Stage III unresectable Epidermal Growth Factor Receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) ^IND

Pembrolizumab

Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with Stage IB (T2a ≥ 4 cm), II or IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete resection. ^IND Extension of indication to include in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant, treatment of resectable stage II, IIIA, or IIIB (T3 4N2) non-small cell lung carcinoma in adults. ^IND

Selpercatinib ^IND Serplulimab Sugemalimab

Tislelizumab

2L NSCLC (mono): As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults 1L non-squamous NSCLC (combi): In combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of locally advanced or metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations 1L squamous NSCLC (combi): In combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of locally advanced or metastatic squamous NSCLC in adults

Toripalimab ^IND Trastuzumab deruxtecan ^IND Tremelimumab

Benralizumab ^IND Gefapixant Nintedanib ^IND Pamrevlumab Pirfenidone ^IND Riociguat ^IND Sotatercept Tadalafil ^IND Tocilizumab ^IND

ALXN1840 Afamelanotide ^IND Avalglucosidase alfa Bardoxolone Methyl Cipaglucosidase alfa Empagliflozine ^IND Fezolinetant Fosdenopterin Leriglitazone Liraglutide ^IND Lonafarnib Octreotide Olenasufligene relduparvovec Olipudase alfa Palopegteriparatide Palovarotene Pegunigalsidase alfa RGX-121 Somapacitan Somatrogon Sparsentan

Belantamab mafodotin ^IND Ciltacabtagene autoleucel Daratumumab ^IND Elranatamab Idecabtagene vicleucel ^IND

Isatuximab

Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ^IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. ^IND

Ixazomib ^IND

Melphalan flufenamide

Pepaxti, in combinatie met dexamethason, is geïndiceerd voor de behandeling van volwassen patiënten met multipel myeloom die minstens drie eerdere therapielijnen hebben gekregen, bij wie de ziekte refractair is voor ten minste één proteasoomremmer, één immunomodulerend middel, één antiCD38-monoklonaal antilichaam, en die tijdens of na hun laatste therapie ziekteprogressie vertoonden. Bij patiënten die eerder een autologe stamceltransplantatie hebben ondergaan, moet er tussen die transplantatie en de progressie ten minste drie jaar zijn verstreken. ^IND Extension of indication to include treatment of patients with Multiple Myeloma who have received at least two prior lines of therapies for PEPAXTI. ^IND

Pomalidomide ^G Selinexor ^IND Talquetamab Teclistamab Thalidomide ^G Venetoclax ^IND Zevorcabtagene autoleucel

Natalizumab ^BS Ublituximab

Bidridistrogene xeboparvovec Dantroleen ^G Daxibotulinumtoxine A Deoxythymidine / deoxycytidine Di-deuterated ethyl linoleate

Eculizumab

Extension of indication to include treatment of paediatric patients aged 6 to less than 18 years with acetylcholine receptor-antibody (AChR-Ab) positive (+) refractory gMG. ^IND Extension of indication to include treatment of paediatric patients with refractory generalised myasthenia gravis (gMG). ^IND

Efgartigimod Omaveloxolone Ravulizumab ^IND Rozanolixizumab Satralizumab ^IND Zilucoplan

Avapritinib ^IND Bomedemstat Momelotinib Navitoclax Pelabresib Pemigatinib ^IND

Cannabidiol Clazosentan Eladocagene exuparvovec Human normal immunoglobulin ^IND Inebilizumab Ravulizumab ^IND Tiratricol Tominersen Trofinetide Troriluzole Vutrisiran

AL102 Afamitresgene autoleucel Durvalumab ^IND Efbemalenograstim alfa Erdafitinib Futibatinib Glucarpidase Ivosidenib Jodium (131I) omburtamab Lenvatinib ^IND Melphalan hydrochloride Nirogacestat

Pembrolizumab

Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. ^IND Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. ^IND indication for treatment with pembrolizumab plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma ^IND

Retifanlimab Selinexor ^IND Sodium thiosulfate Tebentafusp

Tislelizumab

2L locally advanced or metastatic ESCC (esophageal squamous-cell carcinoma) 1L locally advanced or metastatic ESCC (esophageal squamous-cell carcinoma)

Toripalimab

Toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) Toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (“ESCC”)

Avapritinib ^IND Baricitinib ^IND Budesonide modified released capsule Coacillium topical Dupilumab ^IND FCR 001 Leniolisib Lorecivivint Marnetegragene autotemcel Mavorixafor Ritlecitinib Sizavaleucel Sutimlimab Voclosporin

Lenzilumab Luspatercept ^IND Obinutuzumab ^IND

Angiotensin II Dapagliflozine ^IND Etripamil Icosapent ethyl Macitentan ^IND Macitentan / tadalafil Mavacamten Neoatricon (dopamine) Omecamtiv mecarbil Rexlemestrocel-L Rilonacept Sotagliflozine ^IND Valsartan / sacubitril ^IND Vericiguat

Abaloparatide

Treatment of osteoporosis in postmenopausal women at increased risk of fracture Treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Alpelisib Copper histidine Linzagolix ^IND Ospemifene ^IND Pegzilarginase

Semaglutide

For weight management in people with obesity or who are overweight and have other related conditions. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity and body weight above 60 kg. Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. ^IND

Tirzepatide ^IND Vosoritide ^IND

Bentracimab

Concizumab

Hemofilie A en B zonder inhibitors ^IND Hemofilie A met inhibitors en hemofilie B met inhibitors

Crizanlizumab Crovalimab Danicopan Daprodustat Eculizumab ^BS Efanesoctocog alfa Efgartigimod Exagamglogene autotemcel Ferumoxytol Hydroxycarbamide ^IND Iptacopan Luspatercept ^IND Methoxy polyethylene glycol-epoetin beta ^IND Mitapivat Mozafancogene autotemcel

Pegcetacoplan

Paroxysmal nocturnal haemoglobinuria (PNH) Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor ^IND

Ravulizumab

Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. Uitbreiding van de behandeling naar pediatrische patiënten met een lichaamsgewicht van 10kg of meer met paroxismale nachtelijke hemoglobinurie (PNH): - bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit. - bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab. ^IND

UM171 Vadadustat Voxelotor

Dexmedetomidine

Dostarlimab

Stage III or IV non mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (collectively referred to as "ovarian cancer") ^IND Extension of indication to include in combination with platinum -containing chemotherapy the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability -high (MSI -H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy ^IND

Mirvetuximab soravtansine Rucaparib ^IND

Bupivacaine ^IND Buprenorfine ^IND Difluprednate Fasinumab

Lotilaner

Levodopa / carbidopa

Atezolizumab ^IND Darolutamide ^IND Degarelix ^G Enzalutamide ^IND Gozetotide Lutetium (177lu) vipivotide tetraxetan Masitinib Niraparib / abirateron

Olaparib

Treatment in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. ^IND treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone ^IND

Talazoparib ^IND

Baricitinib ^IND

Bimekizumab

Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs), and for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. ^IND Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). ^IND

Cyclobenzaprine hydrochloride Sarilumab ^IND Tocilizumab ^BS

Risdiplam

5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies. Extension of indication to include treatment of patients below 2 months of age. ^IND

Roluperidon Ulotaront

Darleukin fibromun Ipilimumab ^IND Lenvatinib ^IND Lifileucel

Nivolumab

Extension of indication to include adolescent patients aged 12 years and older in treatment of advanced (unresectable or metastatic) melanoma (nivolumab monotherapy), treatment of advanced (unresectable or metastatic) melanoma (nivolumab in combination with ipilimumab) and adjuvant treatment of melanoma (nivolumab monotherapy). ^IND Extension of indication to include OPDIVO for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection. ^IND

Pembrolizumab ^IND Relatlimab / nivolumab Tavokinogene telseplasmid

Baricitinib ^IND Beremagene geperpavec Berkenschorsextract Concentrate of proteolytic enzymes enriched in bromelain ^IND Dabocemagene autoficel Delgocitinib Deucravacitinib Difelikefalin

Dupilumab

Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy. ^IND Extension of indication to include treatment of severe atopic dermatitis in paediatric patients from 6 months to <6 years of age. ^IND

Methotrexaat Piclidenoson Regenerative Skin Tissue Roflumilast topicaal Ruxolitinib phosphate Secukinumab ^IND Sirolimus Spesolimab Tralokinumab ^IND

Daridorexant Natriumoxybaat controlled release Pitolisant ^IND

Abatacept ^IND ECT-001-CB Narsoplimab Omidubicel Plerixafor ^G Tabelecleucel Treosulfan ^IND

Catumaxomab Domvanalimab Nivolumab ^IND

Pembrolizumab

Extension of indication for treatment with pembrolizumab plus trastuzumab in combination with standard of care chemotherapy for adults with HER2 positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma ^IND Extension of indication to include in combination with chemotherapy the first -line treatment of locally advanced unresectable or metastatic HER2 -negative gastric or gastrooesophageal junction adenocarcinoma in adults. ^IND Treatment in the neoadjuvant or adjuvant setting of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. ^IND

Tislelizumab ^IND Trastuzumab deruxtecan ^IND Zolbetuximab

Selpercatinib

Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer in the first-line setting for Retsevmo. ^IND Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) ^IND

Selpercatinib ^IND

Dasatinib ^IND Diazoxide choline (controlled-release tablet) Eplontersen Ibrutinib ^IND Levonorgestrel ^G Linzagolix Lonapegsomatropin Lumasiran Mirabegron ^IND Pirfenidone ^G Relugolix / estradiol / norethisterone acetaat ^IND Relugolix / estradiol / norethisteronen Sofpironium bromide Tagraxofusp Vibegron

Bizalimogene ralaplasmid Bulevirtide

Letermovir

Extension of indication to include treatment of prophylaxis of cytomegalovirus in kidney transplant recipients (KTR) for PREVYMIS. ^IND Extension of Letermovir From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant ^IND

Lonafarnib ^IND Maribavir

Nirsevimab

Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season. Extension of indication to include treatment of children up to 24 months of age who remain vulnerable to severe Respiratory Syncytial Virus (RSV) disease through their second RSV season ^IND

Posoleucel Tenofovir alafenamide ^IND

Published on 6 June 2023

ADHD

ALL

ALS

AML / MDS

Aggressive non-Hodgkin’s lymphoma

Antithrombotic medications

Asthma

Bacterial infections

Bladder cancer

Durvalumab

Bowel diseases

Risankizumab

Brain cancer

Breast cancer

Sacituzumab govitecan

Trastuzumab deruxtecan

CLL

Acalabrutinib

Zanubrutinib

CML

COPD

COVID-19

Casirivimab / imdevimab

Remdesivir

Tixagevimab / cilgavimab

Cervical cancer

Colon cancer

Cystic fibrosis

Dementia

Depression

Diabetes

Duchenne

Epilepsy

Eye disorders

Aflibercept

Faricimab

Ranibizumab

Fungal infections

HIV

Head and neck cancer

Headache

Rimegepant

Hemostasis promoting medication

Hodgkin's lymphoma

Indolent non-Hodgkin’s lymphoma

Infectious diseases other

Kidney cancer

Pembrolizumab

Lipid-lowering medications

Liver cancer

Durvalumab

Liver diseases

Maralixibat

Lung cancer

Atezolizumab

Cemiplimab

Durvalumab

Osimertinib

Pembrolizumab

Tislelizumab

Lung diseases other

Metabolic diseases

Multiple Myeloma

Isatuximab

Melphalan flufenamide

Multiple sclerosis

Muscular diseases other

Eculizumab

Myeloproliferative disorders

Neurological disorders other

Oncology other

Pembrolizumab

Tislelizumab

Toripalimab

Other chronic immune diseases

Other hematology

Other medication for cardiovascular diseases

Other metabolism and Endocrinology

Abaloparatide